title: Comments on Berry et al.'s response-adaptive randomization platform trial for Ebola.
authors.affiliation: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA ebrittain@niaid.nih.gov.
authors.forename: Erica H
authors.initials: EH
authors.lastname: Brittain
authors.affiliation: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Proschan
mesh_terms: D019142:Hemorrhagic Fever, Ebola / Q000628:therapy*; D006801:Humans; D011897:Random Allocation; D016032:Randomized Controlled Trials as Topic; D012107:Research Design